- SCP22: Australian response to GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on Inventions
- WIPO SCP22: KEI statement on GRULAC proposal (SCP/22/5)
- SCP22: India’s Intervention on inventive step (SCP/22/3)
- SCP22: Opening statement of the Group of Latin American and Caribbean Countries
- USTR proposals in TPP are in conflict with U.S. Supreme Court decisions on State Sovereign Immunity
- Eleven of the 28 House democrats supporting Fast Track write USTR about Medicine IPR issues
- WIPO Standing Committee on the Law of Patents: What's on the agenda?
- Sanders offers amendment to create compulsory licenses on medical inventions, for veterans
- KEI letter to Register of Copyrights, USPTO and OSTP on copyright issues in TPP
- Mylan criticisms of the TPP provisions as regards generic medicines, warns USTR on "lazy drafting"
KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricingSubmitted by Claire Cassedy on 21. April 2015 - 15:02
On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.
Yesterday, Politico published this story:
Leaked digital single market’s ‘evidence file’ reveals Commission’s ambitions. Documents show policy came before evidence for cybersecurity measures.
By ZOYA SHEFTALOVICH 20/4/15, 1:29 PM CET Updated 21/4/15, 11:33 AM CET
WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based ModelsSubmitted by thiru on 21. April 2015 - 4:00
On Tuesday, 21 April 2015, the 15th session of the World Intellectual Property Organization's (WIPO) Committee on Development and Intellectual Property (CDIP) considered the Evaluation Report for the Project on Open Collaborative Projects and IP-Based Models (CDIP/15/3). This project on open collaborate development models is based on Recommendation 36 of the WIPO which states,
Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?Submitted by KEI Staff on 20. April 2015 - 17:02
The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.
Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.
Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices
20 April 2015
Dear members of the WHO Expert Committee and the WHO secretariat,
State of California considers AB463, a bill to require disclosure of drug development costs, and more economic dataSubmitted by James Love on 17. April 2015 - 6:35
This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.
A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.
BILL NUMBER: AB 463
INTRODUCED BILL TEXT
INTRODUCED BY Assembly Member Chiu
FEBRUARY 23, 2015
This from the Wikileaks Sony Archive:
An email from Keith Weaver, the "Executive Vice President, Worldwide Government Affairs at Sony Pictures Entertainment, provide an illustration the practical art of doing "Government Affairs," meeting "goals" for fundraisers, trying to avoid making "personal" contributions, and wondering if the donations were to much focused on another company's purchase of policy" "smells a little bit like a Disney play regarding corp. tax reform".
From: Weaver, Keith
Sent: Tuesday, August 26, 2014 5:23 PM
To: Weil, Leah
Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"Submitted by KEI Staff on 16. April 2015 - 13:32
In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:
The following attached letter [PDF ], from KEI and Public Citizen, asks the NIH to impose certain conditions on an exclusive license on NIH owned patents for a drug to treat the hepatitis C virus (HCV). The NIH wants to license the patents to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. Other than the patents involved, the NIH requires people to sign a non-disclosure to know more about the deal.
TRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovationSubmitted by thiru on 30. March 2015 - 3:25
In advance of the World Trade Organization's October 2014 session of the TRIPS Council, the European Union, Switzerland and the United States made a written request to the TRIPS Council to discuss "Intellectual Property and Innovation: Promoting Awareness; Case Studies" under agenda item 12. This marked the 7th time that the United States tabled an item to the TRIPS Council relating to intellectual property or innovation.
In the context of these October 2014 discussions of Intellectual Property and Innovation, the Government of India delivered the following intervention asserting that,
Twenty groups write Congress, no fast track without public access to trade agreement negotiating textsSubmitted by James Love on 20. March 2015 - 15:09
Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.
Among other things, the groups said:
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies -- AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.
HRC28: Statement of the European Union- Cultural Rights (Response to SR Report on Copyright and Right to Science and Culture)Submitted by thiru on 12. March 2015 - 10:56
On Wednesday, 11 March 2015, Oliver Hall-Allen, First Counsellor, Delegation of the European Union to the United Nations Office in Geneva delivered the following statement in response to the presentation of the Special Rapporteur in the Field of Cultural Rights (Farida Shaheed) on her Report on Copyright policy and the right to science and culture (A/HRC/28/57).
Oliver Hall-Allen (blue tie, white shirt), First Counsellor, Delegation of the European Union to the United Nations Office in Geneva
HRC28: Statement of the United States of America - Cultural Rights (Response to SR Report on Copyright and Right to Culture)Submitted by thiru on 11. March 2015 - 18:19
On Wednesday, 11 March 2015, Ambassador Keith Harper, U.S. Representative to the Human Rights Council, delivered the following statement to the 28th Session of the Human Rights Council on the topic of cultural rights.